AMRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Buy now: the broader trend is still constructive (SMA_5 > SMA_20 > SMA_200) and Wall Street price targets ($37\u2013$45, newest $41) imply meaningful upside from $31.44.", "Options positioning is distinctly bullish (very low put/call ratios), supporting a near-term upward bias despite mixed momentum signals.", "Near-term trade map: support around $30.46; a reclaim/hold above the $32.02 pivot improves odds of a push toward $33.57 (R1)."]
["Trend: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the intermediate trend remains up.", "Momentum: MACD histogram -0.0313 and negatively expanding = bearish/weakening momentum in the very near term (risk of chop/pullback).", "RSI(6) 46.5 = neutral; not oversold, so no \u201cforced bounce\u201d signal, but also not overbought.", "Key levels: Pivot $32.015 (near-term line in the sand). Support S1 $30.456 then S2 $29.494. Resistance R1 $33.574 then R2 $34.536.", "Intellectia Proprietary Trading Signals: No strong model-driven buy today, so the case relies on trend/positioning rather than a high-conviction quant trigger.", "Pattern-based forward odds (given dataset): modest expected drift (about +0.17% next day, +1.02% next week, +2% next month)."]
on 2026-03-02 after hours (Est. EPS 0.
could re-rate the stock if margins/EBITDA execution holds."]
["Short-term momentum is weakening (MACD negative and expanding), increasing odds of a dip toward $30.46 support before a cleaner breakout.", "No supportive near-term news flow in the last week; absent a catalyst, the stock may trade technically around the $32 pivot.", "Sector/project execution risk (timing/permits/financing) can pressure near-term results even with a strong long-term pipeline (implied by analyst commentary)."]
["Latest reported quarter: 2025/Q3.", "Revenue: $525.99M, +5.01% YoY (steady growth).", "Net income: $18.51M, +5.30% YoY (profitability improving in line with revenue).", "EPS: $0.35, +6.06% YoY (slightly faster than revenue, positive operating leverage).", "Gross margin: 16.03%, up 4.09% YoY (constructive margin trend)."]
["Recent trend: clearly improving/constructive\u2014multiple target raises and a new Overweight initiation.", "2026-01-23: Cantor Fitzgerald initiated Overweight, PT $41 (multi-year investment cycle tailwinds; Ameresco positioned as a clean-energy infrastructure platform).", "2025-12-03: Roth Capital reiterated Buy, PT $45 (views stock as undervalued/mispriced; expects profitability acceleration).", "2025-12-03: UBS raised PT to $40 from $23, kept Neutral (acknowledges strong demand/backlog and long-term growth, but rating suggests some valuation/execution caution).", "2025-11-14: Stifel raised PT to $37, kept Buy (stronger-than-expected Q3 EBITDA; guidance reiterated).", "Wall Street pros: durable tailwinds + backlog visibility + improving profitability/margins. Cons: execution/timing risk and at least one major shop (UBS) still sits at Neutral despite higher PT."]
